Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | GUSB | P08236 | 1/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732739 | 0.92 | MRGPRX4 (0.56) | MAOBNR4A2PTPN1SMPD1MRGPRX4 | |
| SCHEMBL5734492 | 0.88 | NR1H4 (0.48) | MAOBNR4A2PTPN1SMPD1KMT2A | |
| SCHEMBL5733091 | 0.84 | ERCC5 (0.57) | MEN1KMT2A | |
| SCHEMBL5733413 | 0.84 | RAB9A (0.52) | MEN1KMT2ANR1H4 | |
| SCHEMBL5733382 | 0.83 | NR4A2 (0.64) | MAOBNR4A2PTPN1MEN1KMT2A | |
| SCHEMBL5732667 | 0.82 | CES2 (0.57) | MEN1KMT2A | |
| SCHEMBL6490457 | 0.81 | MAOB (0.59) | MAOBNR4A2PTPN1SMPD1SRD5A2 | |
| SCHEMBL5734534 | 0.81 | LMNA (0.53) | PTPN1KMT2AMRGPRX4 | |
| SCHEMBL2503352 | 0.81 | MAOB (0.69) | MAOBNR4A2PTPN1SMPD1SRD5A2 | |
| SCHEMBL2152475 | 0.81 | MAOB (0.73) | MAOBNR4A2PTPN1SMPD1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1863768-A | Prostaglandin analogs as agonists of the EP4 receptor | HOFFMANN LA ROCHE (CH) | 2006-11-15 | — | — | CN | disclosed |
| US-6900336-B2 | 8-aza-11-deoxy prostaglandin analogues | SYNTEX (U.S.A.) LLC (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1409455-A1 | PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-21 | — | — | EP | disclosed |
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | SYNTEX (U.S.A.) LLC | 2003-06-26 | — | — | US | disclosed |
| WO-2003008377-A1 | PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | PTGER4, FFAR4, PTGER1 | MAOB 2161/4885NR4A2 166/4885PTPN1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.